fbpx
Manufacturing

World‑class T‑cell
Manufacturing

Designed to Global Regulatory Standards - Commissioned and Qualified to Support Clinical Development

Our dedicated, expandable Atara T-cell Operations and Manufacturing (ATOM) facility located in Thousand Oaks, CA is designed to meet global regulatory standards and has the flexibility to produce multiple T-cell and CAR T immunotherapies. Our integrated research and process science enables rapid development while also leveraging research collaborations.

Our T-cell product candidates require blood from healthy, consenting third-party donors as starting materials. The manufacturing process involves co-culturing and incubating viral or cancer-specific antigen presenting B-cells collected from the blood of third party-donors with T‑Cells collected from the same donor, all under Good Tissue Practices, or GTPs. A CTL (cytotoxic T-cell) library is made for each development program.

How Our Investigational T‑Cells are Developed

How Our Investigational T‑Cells are Developed
1 EBV T‑Cells are selected and expanded from the peripheral blood mononuclear cells (PBMCs) of immunologically diverse donors (3rd party donors) with healthy immune systems.
2 After separating the B and T‑Cells, the B cells are transformed into antigen presenting cells (APCs) by exposing them to EBV antigens.
3 The T‑Cells from this same donor are exposed to the APCs that now express the EBV antigens, stimulating T cell activation and expansion. The T‑Cells that are unable to recognize the antigen are not activated.
4 The activated and expanded T‑Cells now will specifically recognize the EBV antigen.
5 The T‑Cells are characterized by their EBV specificity and HLA restriction profiles and cryopreserved in a library.
EBV T‑Cells are selected and expanded from the peripheral blood mononuclear cells (PBMCs) of immunologically diverse donors (3rd party donors) with healthy immune systems.
After separating the B and T‑Cells, the B cells are transformed into antigen presenting cells (APCs) by exposing them to EBV antigens.
The T‑Cells from this same donor are exposed to the APCs that now express the EBV antigens, stimulating T cell activation and expansion. The T‑Cells that are unable to recognize the antigen are not activated.
The activated and expanded T‑Cells now will specifically recognize the EBV antigen.
The T‑Cells are characterized by their EBV specificity and HLA restriction profiles and cryopreserved in a library.
Publications

Developing Investigational T-cell Immunotherapies Based on Clinical Research

A collection of publications and presentations cover various areas of interest.

Developing Investigational T-cell Immunotherapies Based on Clinical Research